/
Unless otherwise stated in this Annual Report or the context otherwise requires, references to: GeneDx Holdings refer to GeneDx Holdings Corp., a Delaware corporation; Legacy GeneDx refer to GeneDx, LLC, a Delaware limited liability company, which we acquired on April 29, 2022 (the Acquisition ); Legacy Sema4 refer to Sema4 OpCo Inc., a Delaware corporation, which consummated the business combi…
The business is unprofitable at the operating level (-3.06% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 40.0% YoY with margins expanding 4.5pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$443M
▲ +40.0% YoY
Net Income (TTM)
-$78M
▲ +59.8% YoY
Op. Margin
-14.91%
▲ +4.5pp YoY
ROIC
-14.41%
▲ +2.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$29M
▲ +142.0% YoY
Op. Cash Flow (TTM)
-$9M
▲ +216.8% YoY
Net Debt
-$74M
Net Cash Position
Cash & Equiv.
$171M
5Y CAGR: +19.0%
Continue Research